




Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 30 day of October 2003.

s/


Bonnie Acosta

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Theodore Johnson, Jr., et al.

Serial No.: 10/626,827

Confirmation No.: TBA

Filed: July 23, 2003

For: ANTIPICORNAVIRAL COMPOUNDS
AND COMPOSITIONS, THEIR
PHARMACEUTICAL USES, AND MATERIALS
FOR THEIR SYNTHESIS

Group Art Unit: TBA

Examiner: TBA

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the documents listed on the attached substitute Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified in 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.


It is respectfully requested that the Examiner confirm consideration of the cited documents by

initialing the attached substitute Form PTO-1449 and returning a copy of the initialed form to the Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified in 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,


Date: October 30, 2003


Karl O. Neidert
Attorney For Applicant
Registration No. 39,313

Agouron Pharmaceuticals, Inc.
A Pfizer Company
Legal Division, Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-8060
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/626,827
Filing Date	July 23, 2003
First Named Inventor	Theodore O. Johnson, Jr.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	0055-01-US

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,856,530	01-05-1999	Agouron Pharmaceuticals, Inc.	
	AB	5,962,487	10-05-1999	Agouron Pharmaceuticals, Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	BIRCH, G. et al., "Purification Of Recombinant Human Rhinovirus 14 3C Protease Expressed In Escherichia Coli" <i>Protein Expression And Purification</i> 1995, 609-618, vol. 6.	
	AD	BUNDGAARD, H. et al., Design of Prodrugs, 1985, Elsevier Press.	
	AE	DIANA, G. et al., "Picornavirus Inhibitors: Trifluoromethyl Substitution Provides A Global Protective Effect Against Hepatic Metabolism" <i>J. Med. Chem.</i> 1995, 1355-1371, Vol. 38.	
	AF	DRAGOVICH, P. et al., "Solid-Phase Synthesis Of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 1: Optimization Of Tripeptides Incorporating N-Terminal Amides" <i>Bioorganic & Medicinal Chemistry</i> 1999, 589-598, vol. 7.	
	AG	DRAGOVICH, P. et al., "Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure-Activity Studies Of Ketomethylene-Containing Peptidomimetics" <i>J. Med. Chem.</i> 1999, 1203-1212, vol. 42.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Complete if Known

Application Number	10/626,827
Filing Date	July 23, 2003
First Named Inventor	Theodore O. Johnson, Jr.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	0055-01-US

(Use as many sheets as necessary)

AH

DRAGOVICH, P. et al., "Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P₁ Lactam Moieties as L-Glutamine Replacements," *J. Med. Chem.* 1999, 1213-1224, vol. 42.

AI

WEISLOW, et al., *J. Natl. Cancer Inst.* 1989, 577-586, vol. 81.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**